{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:45:27Z","timestamp":1762980327076},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The optimal degree of testosterone suppression in patients with prostate cancer undergoing androgen deprivation therapy remains in question. Furthermore, serum free testosterone, which is the active form of testosterone, seems to correlate with intraprostatic testosterone. Here we compared free and total serum testosterone as predictors of survival free of castration resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Total testosterone (chemiluminescent assay, lower sensitivity 10\u2009ng\/dl) and free testosterone (analogue\u2010ligand radioimmunoassay, lower sensitivity 0.05\u2009pg\/ml) were determined at 6 months of LHRH agonist treatment in a prospective cohort of 126 patients with prostate cancer. During a mean follow\u2010up of 67 months (9\u2013120), 75 (59.5%) events of castration\u2010resistant progression were identified. Multivariate analysis and survival analysis according to total testosterone cutoffs of 50, 32, and 20\u2009ng\/dl, and free testosterone cutoffs of 1.7, 1.1, and 0.7\u2009pg\/ml were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Metastatic spread was the most powerful predictor of castration resistance, HR: 2.09 (95%CI: 1.18\u20133.72), <jats:italic>P<\/jats:italic>\u2009=\u20090.012. Gleason score, baseline PSA and PSA at 6 months were also independents predictors, but not free and total testosterone. Stratified analysis was conducted on the basis of the status of metastatic diseases and free testosterone was found to be an independent predictor of survival free of castration resistance in the subgroup of patients without metastasis, HR: 2.12 (95%CI: 1.16\u20133.85), <jats:italic>P<\/jats:italic>\u2009=\u20090.014. The lowest threshold of free testosterone which showed significant differences was 1.7\u2009pg\/ml, <jats:italic>P<\/jats:italic>\u2009=\u20090.003.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Free testosterone at 6 months of LHRH agonist treatment seems to be a better surrogate than total testosterone to predict castration resistance in no metastatic prostate cancer patients. <jats:italic>Prostate 77:114\u2013120, 2017<\/jats:italic>. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.23256","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T05:17:22Z","timestamp":1477977442000},"page":"114-120","source":"Crossref","is-referenced-by-count":9,"title":["Free Testosterone During Androgen Deprivation Therapy Predicts Castration\u2010Resistant Progression Better Than Total Testosterone"],"prefix":"10.1002","volume":"77","author":[{"given":"Lucas","family":"Regis","sequence":"first","affiliation":[{"name":"Department of Urology Vall d'Hebron University Hospital Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Planas","sequence":"additional","affiliation":[{"name":"Department of Urology Vall d'Hebron University Hospital Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Carles","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Vall d'Hebron University Hospital Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Vall d'Hebron University Hospital Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inma","family":"Comas","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Vall d'Hebron University Hospital Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Vall d'Hebron University Hospital Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Morote","sequence":"additional","affiliation":[{"name":"Department of Urology Vall d'Hebron University Hospital Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"293","article-title":"Studies on prostatic cancer I. The effect of castration, of estrogen, and of androgen injection on serum phosphatises in metastatic carcinoma of the prostate","volume":"1","author":"Huggins C","year":"1941","journal-title":"Cancer Res"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.03.007"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9810"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10719.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/clinchem\/33.8.1372","article-title":"Total testosterone, free\u2010androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise\u2010normal women with altered binding of sex\u2010hormone\u2010binding globulin","volume":"33","author":"Wilke TJ","year":"1987","journal-title":"Clin Chem"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00793-7"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11190.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-10-3-232"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.10.6079"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800094-6.00002-9"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450115666141024114736"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2005.04.004"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.05.129"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08814.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2013.01.002"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.471"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.03.120"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.2973"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12623"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032175"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.02.001"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-69080-3_21"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990110103"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10652.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08062.x"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23256","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T01:32:56Z","timestamp":1696469576000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1002\/pros.23256"],"URL":"https:\/\/doi.org\/10.1002\/pros.23256","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}